For families affected by phenylketonuria (PKU), newborn screening can mean the difference between a healthy future and lifelong complications. PKU is a rare inherited metabolic disorder that leads to toxic buildup of phenylalanine (Phe) in the blood, which can result in serious neurological and cognitive complications if not carefully managed. The disease is often cited as one of the clearest examples of why newborn screening is so important—early diagnosis allows treatment to begin before irreversible damage can occur.
Now, a new investigational gene editing program is aiming to go a step further: addressing the root genetic cause of PKU.
Beam Therapeutics, a company developing precision genetic medicines through its base editing technology, recently announced BEAM-304, a liver-targeted base editing program designed to directly correct mutations in the PAH gene that cause PKU.
Current treatment for PKU typically includes lifelong dietary restriction and medical foods, as well as approved pharmacologic therapies for certain patients. Despite these options, a significant unmet need remains due to treatment burden, variable efficacy, and the challenges of long-term adherence. Many individuals and families continue to face daily management complexities and ongoing health risks.
BEAM-304 is being developed with the goal of reducing toxic Phe levels to within recommended guidelines by correcting the underlying mutation, potentially allowing normalization of diet and easing the long-term burden for patients and their caregivers.
Current treatment for PKU includes lifelong dietary management and medical foods, as well as approved pharmacologic therapies for certain patients. Despite these options, a significant unmet need remains due to treatment burden, variable efficacy, and the challenges of long-term adherence. Many individuals and families continue to face daily management complexities and ongoing health risks.
The program will initially focus on two of the most prevalent PAH mutations, which together account for nearly half of U.S. patients with PKU. In preclinical studies, mutation-specific base editors normalized plasma Phe levels in mouse models at clinically relevant doses, with robust on-target editing in the liver.
Notably, Beam plans to develop multiple mutation-specific base editors within a single clinical program — an approach intended to efficiently expand treatment to additional PKU-causing variants over time. An Investigational New Drug (IND) application is anticipated in 2026, with a planned Phase 1/2 trial expected to initially evaluate safety, tolerability, and reduction of blood Phe levels in patients with common PKU mutations.
While this program is still in development and not yet approved, it reflects continued momentum in rare disease research and renewed hope that genetic medicines may one day offer durable, potentially one-time treatments for people living with PKU.
We will continue to follow developments in the PKU community and share updates as they become available.
